MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
IMA — ImageneBio, Inc. Common Stock
NasdaqImageneBio, Inc. Common Stock
$4.60
+0.02(+0.43%)
- O
- 4.69
- H
- 4.69
- L
- 4.56
- V
- 7.81K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About IMA
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateJul 28, 2025
Employees18
Stock ExchangeNasdaq
Ticker SymbolIMA
Websitehttps://www.imagenebio.com
Key Financial Statistics
| Market Cap | $52.22M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $3.94 - $9.10 |
| 52-Week Avg Volume | 115.1K |
| VWAP | $4.62 |
| Transactions | 282 |
| Total Recorded Bars | 1,387 days |